The investigation elucidated a notable enhancement in PFS upon the coadministration of Abemaciclib with an aromatase inhibitor, in contrast to the use of the aromatase inhibitor in isolation, among patients afflicted by advanced breast cancer characterized by HR-positive and HER2-negative status [117]. This evidence concerns the gene CYP19A1 and breast carcinoma.